Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05191472
Title Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Alfred Chung, MD
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.